Valuation: Tarsus Pharmaceuticals, Inc.

Market Cap 3.33B 2.99B 2.73B 2.49B 4.69B 313B 4.84B 32.89B 13.12B 167B 12.5B 12.23B 527B P/E 2026 *
-4.45x
P/E 2027 * 255x
Enterprise Value 2.99B 2.68B 2.45B 2.24B 4.22B 281B 4.35B 29.57B 11.79B 150B 11.23B 10.99B 474B EV / Sales 2026 *
4.05x
EV / Sales 2027 * 3.1x
Free-Float
97.34%
Yield 2026 *
-
Yield 2027 * -
1 day-0.29%
1 week-9.65%
Current month-9.65%
1 month-8.74%
3 months+3.52%
6 months+4.43%
Current year-17.40%
1 week 65.34
Extreme 65.3425
76.09
1 month 65.34
Extreme 65.3425
76.64
Current year 53.89
Extreme 53.89
91.53
1 year 53.89
Extreme 53.89
91.53
3 years 15.47
Extreme 15.47
91.53
5 years 10.8
Extreme 10.8001
91.53
10 years 10.8
Extreme 10.8001
91.53
Manager TitleAgeSince
Chief Executive Officer 48 31/08/2018
Director of Finance/CFO 65 23/04/2023
Chief Tech/Sci/R&D Officer 47 03/11/2024
Director TitleAgeSince
Chairman 48 01/12/2022
Director/Board Member 71 30/11/2019
Director/Board Member 80 31/12/2016
Date Insider Type Main position Quantity % Market Cap. Importance
15/09/26 Exercice

Director

604 0.0014%
15/09/26 Exercice

Director

12,902 0.0294%
15/09/26 Exercice

Director

402 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%-9.65%-0.68%+322.42% 3.33B
+0.20%-3.57%+45.81%+129.65% 1,216B
+1.02%+0.66%+47.09%+81.29% 656B
+0.78%-1.42%+32.72%+105.89% 509B
-0.36%-3.25%+47.17%+64.58% 384B
-0.09%-1.68%+71.38%+40.90% 362B
-0.78%-0.52%+30.57%+57.98% 311B
-0.80%-0.21%+8.54%+35.56% 293B
-0.03%-1.07%+46.09%+68.98% 249B
+0.36%-1.37%+36.43%+107.48% 208B
Average -0.08%-0.36%+36.51%+101.47% 419.11B
Weighted average by Cap. +0.10%+0.03%+42.53%+89.11%

Financials

2026 *2027 *
Net sales 739M 663M 606M 553M 1.04B 69.5B 1.08B 7.31B 2.91B 37.09B 2.78B 2.72B 117B 920M 825M 754M 688M 1.3B 86.49B 1.34B 9.09B 3.63B 46.15B 3.45B 3.38B 146B
Net income -695M -624M -570M -520M -980M -65.36B -1.01B -6.87B -2.74B -34.88B -2.61B -2.55B -110B 12.99M 11.65M 10.65M 9.72M 18.31M 1.22B 18.89M 128M 51.17M 651M 48.75M 47.7M 2.06B
Net Debt -336M -302M -276M -252M -474M -31.61B -489M -3.32B -1.32B -16.87B -1.26B -1.24B -53.24B -476M -427M -390M -356M -671M -44.71B -692M -4.7B -1.87B -23.86B -1.79B -1.75B -75.31B
Projected Income Statement - Annual - Tarsus Pharmaceuticals, Inc.
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic.
Employees
370
Date Price Change Volume
06/11/26 US$67.45 -0.10% 309,096
05/11/26 US$67.52 -2.24% 1,716,286
04/11/26 US$69.07 -4.91% 2,550,743
03/11/26 US$72.64 -0.93% 755,780
02/11/26 US$73.32 -2.04% 428,692
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Tarsus Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
67.52USD
Average target price
99.33USD
Spread / Average Target
+47.12%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Tarsus Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. TARS Stock